Triclosan

Summary

Triclosan (CHEMBL849) is an approved small-molecule antibacterial agent (ATC D08AE04); indicated across 5 conditions including periodontitis and mucositis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D08AE04 (+1 more)
• Indications: 5 conditions
• Clinical trials: 40
• Chemistry: 289.5 Da · C12H7Cl3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL849
Name	Triclosan
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5564
ChEBI	CHEBI:164200
ATC	D08AE04, D09AA06
Molecular formula	C12H7Cl3O2
Molecular weight	289.5
InChIKey	XEFQLINVKFYRCS-UHFFFAOYSA-N

SMILES: C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl

IUPAC name: 5-chloro-2-(2,4-dichlorophenoxy)phenol

ChEBI definition: An aromatic ether that is phenol which is substituted at C-5 by a chloro group and at C-2 by a 2,4-dichlorophenoxy group. It is widely used as a preservative and antimicrobial agent in personal care products such as soaps, skin creams, toothpaste and deodorants as well as in household items such as plastic chopping boards, sports equipment and shoes.

Pharmacological roles (ChEBI): antibacterial agent, fungicide, EC 1.5.1.3 (dihydrofolate reductase) inhibitor, antimalarial, EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor, drug allergen.

Other ChEBI roles (chemical / environmental): xenobiotic, persistent organic pollutant.

Also known as: Aquasept, CH 3565, CH-3565, Cloxifenol, DNDI1246774, Gamophen, Innoxa, Manusept, NSC-759151, Skinsan, Stri-dex cleansing bar, Tegusept

Patent coverage: 25,267 distinct patent families (77,720 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 75,181 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI, Microtubule-associated protein tau, Prelamin-A/C, Ferritin light chain, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Endoplasmic reticulum chaperone BiP, Enoyl-[acyl-carrier-protein] reductase [NADH], Enoyl-[acyl-carrier-protein] reductase [NADH] FabI, Thromboxane A2 receptor, Progesterone receptor.

Bioactivity

ChEMBL activities: 36 potent at pChembl ≥ 5 of 45 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0AEK4	8.3	IC50	5	nM	CHEMBL_ACT_13318324
Q6GI75	8.3	Ki	5	nM	CHEMBL_ACT_24994702
LMNA	7.5	Potency	31.6	nM	CHEMBL_ACT_3626203
Q6GI75	7.23	IC50	59	nM	CHEMBL_ACT_12158714
CBR1	7.22	Ki	60	nM	CHEMBL_ACT_2393925
Q6GI75	7.16	IC50	70	nM	CHEMBL_ACT_1056039
Q6GI75	7.16	IC50	70	nM	CHEMBL_ACT_65124
P0AEK4	6.77	IC50	170	nM	CHEMBL_ACT_12160742
P9WGR1	6.7	IC50	200	nM	CHEMBL_ACT_13825811
P9WGR1	6.7	Ki	200	nM	CHEMBL_ACT_18390385
P9WGR1	6.7	Ki	200	nM	CHEMBL_ACT_2169607
P9WGR1	6.7	Ki	200	nM	CHEMBL_ACT_24994755
P9WGR1	6.7	Ki	200	nM	CHEMBL_ACT_25040271
MAPT	6.7	Potency	199.5	nM	CHEMBL_ACT_4511798
P9WGR1	6.66	Ki	220	nM	CHEMBL_ACT_18390296
CBR1	6.4	IC50	400	nM	CHEMBL_ACT_2393924
P0AEK4	6.37	IC50	430	nM	CHEMBL_ACT_1234830
P0AEK4	6.37	IC50	430	nM	CHEMBL_ACT_956255
Q6GI75	6.36	IC50	440	nM	CHEMBL_ACT_15736895
TTR	6.32	Kd	484	nM	CHEMBL_ACT_29145687
P54616	6.3	IC50	500	nM	CHEMBL_ACT_2172114
P9WGR1	6.2	IC50	630	nM	CHEMBL_ACT_15105473
SLC6A2	6.16	AC50	700	nM	CHEMBL_ACT_25144615
P0AEK4	6.05	IC50	900	nM	CHEMBL_ACT_1990180
P9WGR1	6	IC50	1000	nM	CHEMBL_ACT_18390297
P9WGR1	6	IC50	1000	nM	CHEMBL_ACT_22422039
Q6GI75	5.96	IC50	1100	nM	CHEMBL_ACT_1234829
Q6GI75	5.96	IC50	1100	nM	CHEMBL_ACT_956254
P9WGR1	5.52	IC50	3000	nM	CHEMBL_ACT_2309410
P9WGR1	5.21	IC50	6140	nM	CHEMBL_ACT_19489070

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
periodontitis	3	MONDO:0005076	EFO:0000649
mucositis	3	MONDO:0020579	EFO:1001898
gingivitis	3	MONDO:0002508	MONDO:0002508
periodontal disorder	3	MONDO:0002635	MONDO:0002635
allergic disease	3	MONDO:0005271	MONDO:0005271

Clinical trials

Total trials: 40.

Phase distribution

Phase	Trials
PHASE3	25
PHASE4	8
Not specified	6
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00762528	PHASE4	COMPLETED	Compare Anti-inflammatory Dentifrices
NCT00941668	PHASE4	COMPLETED	Evaluate Inflammation Caused by Gingivitis in Adults
NCT01457859	PHASE4	UNKNOWN	Effectiveness of Triclosan Coated Sutures in Preventing Leg Wound Infection After Coronary Artery Bypass Surgery
NCT02360995	PHASE4	COMPLETED	The Clinical Investigation of Toothpaste as Compared to Toothpaste and Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical Study in the US
NCT02366689	PHASE4	COMPLETED	Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)
NCT03246776	PHASE4	COMPLETED	Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan
NCT03642353	PHASE4	COMPLETED	Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families.
NCT04538365	PHASE4	COMPLETED	Pre-surgical Antisepsis of Hands After Washing With Triclosan 0.5% Compared to Propan-1-ol 60%
NCT00758290	PHASE3	COMPLETED	Clinical Study to Evaluate Dental Plaque
NCT00758394	PHASE3	COMPLETED	Clinical Study to Compare Dental Plaque Control
NCT00758563	PHASE3	COMPLETED	Train New Examiners Via Modified Gingival Margin Plaque
NCT00759031	PHASE3	COMPLETED	Investigation of Dental Plaque and Gingival Index
NCT00759187	PHASE3	COMPLETED	Evaluate Clinical Research From Commerical Oral Care Products
NCT00761930	PHASE3	COMPLETED	Compare the Clinical Efficacy of Prototype Toothpastes.
NCT00762177	PHASE3	COMPLETED	Investigate Oral Bacteria in Adult Population
NCT00762450	PHASE3	COMPLETED	Effect on Bacterial Glycolytic Acid Formation on Plaque
NCT00762515	PHASE3	COMPLETED	Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes
NCT00762619	PHASE3	COMPLETED	Clinical Study to Examine Brushing on Dental Implants
NCT00762762	PHASE3	COMPLETED	Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population
NCT00762853	PHASE3	COMPLETED	Development of Clinical Method to Triclosan Retention in Plaque Following Brushing
NCT00763048	PHASE3	COMPLETED	Collection of Gingival Crevicular Fluid From Periodontitis Patients
NCT00763165	PHASE3	UNKNOWN	Periodontal Disease and Cardiovascular Disease
NCT00763256	PHASE3	COMPLETED	The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics
NCT00763269	PHASE3	COMPLETED	The Efficacy of a Toothpaste to Reduce Sensitivity
NCT00765167	PHASE3	COMPLETED	Training and Calibration of Dental Examiners
NCT00926029	PHASE3	COMPLETED	Compare the Clinical Efficacy of Prototype Toothpastes
NCT00926328	PHASE3	COMPLETED	Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis
NCT00966953	PHASE3	COMPLETED	Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.
NCT00981825	PHASE3	COMPLETED	Efficacy of Salivary Bacteria and Post Brushing
NCT01024738	PHASE3	COMPLETED	Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse
NCT01072201	PHASE3	COMPLETED	To Access the Effects of Mucositis in Adults With Dental Implants
NCT02193165	PHASE3	COMPLETED	The Clinical Efficacy of Three Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Dental Plaque and Gingivitis
NCT03191721	PHASE3	COMPLETED	Triclosan Toothpaste in the Maintenance Phase of Peri-implantitis Treatment.
NCT01014143	PHASE2	COMPLETED	Evaluating Commercial Anti-Plaque Products and Oral Rinse
NCT07318493	Not specified	RECRUITING	Antiseptic-Coated Sutures and Pancreatic Fistula Risk After Pancreatoduodenectomy
NCT01509976	Not specified	COMPLETED	Triclosan, Triclocarban, and the Microbiota
NCT01799226	Not specified	COMPLETED	Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model
NCT03145610	Not specified	COMPLETED	Impact of a Triclosan-containing Toothpaste During the Progression of Experimental Peri-implant Mucositis
NCT03241407	Not specified	COMPLETED	Triclosan Toothpaste as a Preventive Strategy of Mucositis in Smokers
NCT05105139	Not specified	COMPLETED	Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).